Innovent Biologics' stock soared 5.06% during intraday trading on Thursday, following the release of its first-quarter 2026 financial results.

The company reported total product revenue exceeding RMB3.8 billion for Q1 2026, representing year-over-year growth of over 50%. This robust performance demonstrates the successful execution of the company's "dual-engine" growth strategy, combining domestic business expansion with accelerating global innovation pipeline development.

Revenue growth was driven by rapid sales expansion of five tyrosine kinase inhibitors following their recent inclusion in China's National Reimbursement Drug List, along with strong performance from core products including Xelmei® (Mazdutide Injection), Xinbile® (Tolecimab Injection), and Xinbimin® (Tituyou Monoclonal Antibody N01 Injection). The company is also advancing three high-value potential molecules—IBI363, IBI343, and IBI324—into or toward global multi-center Phase III clinical studies, bolstering its long-term growth prospects.